The FDA approved a test that can help clinicians diagnose Alzheimer's disease early on using a simple blood draw. The test ...

Pfizer is paying $1.25 billion to join the PD-(L1)xVEGF bispecific race. | Pfizer is paying $1.25 billion to join the ...

Analysts at BMO Capital Markets said in a weekend note that a non-invasive blood test could help boost uptake of Alzheimer’s ...

The U.S. Food and Drug Administration has cleared Fujirebio Diagnostics' blood test to diagnose Alzheimer's disease, the ...

The test may make it easier to identify whether people with memory and thinking problems have Alzheimer’s or not.

Eisai has put direct-to-consumer (DTC) advertising at the heart of its ongoing efforts to expand demand for Leqembi. | Eisai ...

U.S. health officials have endorsed the first blood test that can help diagnose Alzheimer’s. The test would help identify ...

The lack of quick and easy tests has until now slowed the roll-out of new Alzheimer’s drugs like Eisai and Biogen’s Leqembi and Eli Lilly’s Kisunla.

The FDA said it has issued its first official green light for a blood test to help diagnose Alzheimer’s disease, adding that ...

Hi, it’s Amber in Hong Kong. Across the strait in Taiwan, breakthrough Alzheimer’s drugs are finally becoming available but ...

Dublin, May 13, 2025 (GLOBE NEWSWIRE) -- The "Leqembi Market Report 2025: Epidemiology, Pipeline Analysis, Market Insights & Forecasts" has been added to ResearchAndMarkets.com's offering.